NCT05268003终止2 期
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- To determine the complete remission (CR) / CR with incomplete count recovery (CRi) rate with the combination of Ponatinib and mini-hyper-CVD chemotherapy and venetoclax.
研究概览
简要总结
The addition of ponatinib to mini-hyper-CVD chemotherapy and venetoclax will improve the complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia
详细描述
OBJECTIVES
The addition of ponatinib to mini-hyper-CVD chemotherapy and venetoclax will improve the complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
Primary Objective:
To assess complete remission (CR) / CR with incomplete count recovery (CRi) rate with the combination of Ponatinib and mini-hyper-CVD chemotherapy and venetoclax.
Secondary Objectives:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with relapsed or refractory T-cell acute lymphoblastic leukemia defined as receiving one or more cytotoxic containing regimens and A. Bone marrow involvement with ≥ 5% lymphoblasts B. Age ≥ 12 Years and greater than 40kg
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- •Adequate organ function
- •Serum total bilirubin ≤1.5 x upper limit of normal (ULN) or ≤3 x ULN for participants with Gilbert's disease
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 x ULN, unless clearly due to disease involvement
- •Creatinine clearance ≥50 mL/min (calculated according to institutional standards or using Cockcroft-Gault or Modification of Diet in Renal Disease (MDRD) formula)
- •Women of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug. Women of non- childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy. Men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug
- •Participants must provide written informed consent
排除标准
- •Participant is pregnant or breastfeeding
- •Participants under 40kg
- •Participants with uncontrolled active infection
- •Hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
- •Major surgery or radiation therapy within 4 weeks prior to the first study dose
- •Systemic chemotherapy/radiotherapy/investigational therapy within 14 days (with the exception of hydroxyurea, dexamethasone, or one dose of cytarabine) prior to starting therapy
- •No clinical, radiological or laboratory evidence of pancreatitis, including:
- •Serum lipase must be <2 times the ULN, and
- •Serum amylase must be <2 times the ULN
- •Symptomatic or untreated leptomeningeal disease or spinal cord compression. Participants with prior h/o CNS disease are eligible as long as no active CNS disease as documented by recent CSF analysis and/or imaging studies.
- •Participants with active heart disease [New York Heart Association (NYHA) class 3-4 as assessed by history and physical examination, unstable angina/stroke/myocardial infarction within the last 6 months]
- •Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
- •Myocardial infarction (MI), stroke, revascularization, unstable angina or transient ischemic attack within 6 months
- •Left ventricular ejection fraction (LVEF) less than 50%
- •Diagnosed or suspected congenital long QT syndrome
- •Clinically significant atrial or ventricular arrhythmias (such as uncontrolled, clinically significant atrial fibrillation, ventricular tachycardia, ventricular fibrillation, or Torsades de pointes) as determined by the treating physician
- •Prolonged QTc interval on pre-entry electrocardiogram (> 480 msec) unless corrected after electrolyte replacement or Currently taking drugs that are known to have a risk of causing prolonged QTc or torsades de pointes (TdP) (unless these can be changed to acceptable alternatives or discontinued)
- •History of venous thromboembolism including deep venous thrombosis or pulmonary embolism within the past 3 months, excluding line-associated DVT of the upper extremity
- •Uncontrolled hypertension (diastolic blood pressure >100mmHg; systolic >150mmHg).
- •10. Uncontrolled hypertriglyceridemia (triglycerides > 450mg/dL)
- •History of another primary invasive malignancy that has not been definitively treated or in remission for at least 2 years. Participants with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses)
- •Taking any medications or herbal supplements that are known to be strong inhibitors (such as fluconazole, ketoconazole, voriconazole, and clarithromycin) or inducers (such as rifampin, rifabutin, phenytoin, carbamazepine, and St. John's Wort) of cytochrome P450 (CYP)3A4 within at least 7 days before the first dose of ponatinib or within 3 days of starting venetoclax.
- •13. Consumed grapefruit, grapefruit products, Seville oranges, or star fruit within 3 days prior to starting venetoclax
- •Malabsorption syndrome or other conditions that preclude enteral route of administration
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the participants inappropriate for enrollment into this study
研究组 & 干预措施
Ponatinib
Experimental
Participants will receive ponatinib (45mg daily) as a single agent for 3 days. These will be called Days -3, -2 and -1
干预措施: Ponatinib (Drug)
Mini-hyper-CVD
Experimental
Chemotherapy will be administered in the inpatient setting, starting on day 1 of each of the cycles 2-8.
干预措施: Mini-hyper CVD (Drug)
Venetoclax
Experimental
Patients will continue venetoclax 400mg daily on days 1-14 of each 28-day cycle.
干预措施: Venetoclax (Drug)
结局指标
主要结局
To determine the complete remission (CR) / CR with incomplete count recovery (CRi) rate with the combination of Ponatinib and mini-hyper-CVD chemotherapy and venetoclax.
时间窗: through study completion, an average of 1 year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAdult Acute Lymphoblastic Leukemia in Complete RemissionB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome PositiveUntreated Adult Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaNCT01424982M.D. Anderson Cancer Center88
终止
1 期
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Acute Lymphoblastic LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 Positivet(9;22)NCT03576547M.D. Anderson Cancer Center9
已完成
2 期
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.BCR-ABL1 Fusion Protein ExpressionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic Leukemiat(9;22)Acute Lymphoblastic LeukemiaNCT00390793M.D. Anderson Cancer Center107
已完成
2 期
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Acute Myeloid LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Myeloid LeukemiaNCT04188405M.D. Anderson Cancer Center20
进行中（未招募）
2 期
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaNCT03147612M.D. Anderson Cancer Center22